• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Clinical management of hepatitis B virus infection correlated with liver transplantation

    2010-06-29 10:12:16JianZhangLinZhouandShuSenZheng

    Jian Zhang, Lin Zhou and Shu-Sen Zheng

    Hangzhou, China

    Clinical management of hepatitis B virus infection correlated with liver transplantation

    Jian Zhang, Lin Zhou and Shu-Sen Zheng

    Hangzhou, China

    BACKGROUND:As a radical cure for post-hepatitis B virus (HBV)-related liver cirrhosis and hepatocellular carcinoma, liver transplantation has been applied in many medical centers. Before the use of effective measures, hepatitis B recurrence and the existence of HBsAg(+) donors, patients with hepatitis B-related diseases are contraindicated for liver transplantation. Application of interferon, hepatitis B immunoglobulin (HBIG), and nucleotide analogues (e.g., lamivudine) has made great progress in the clinical care of HBV. However, there are still many shortcomings such as low viral suppression rate, rising expense, and the induction of HBV tyrosine-methionineaspartate-aspartate (YMDD) mutation. This article systematically reviews the current evidence that immunotherapy, conventional drug combinations, and some special fields of HBV infection correlate with liver transplantation.

    DATA SOURCES:Studies were identified by searching MEDLINE and PubMed for articles using the keywords "hepatitis B virus", "hepatitis B vaccination", "lamivudine", "adefovir", "entecavir", "tenofovir", "HBV genotype", and "liver transplantation" up to October 2009. Additional papers were identified by a manual search of the references from the key articles.

    RESULTS:Hepatitis B vaccine and human monoclonal antibody have very good clinical prospects. Compared with traditional therapies, the new medical regimens have many benefits such as boosting viral suppression rate and decreasing medical expenses. The triple therapy for YMDD mutation also has an excellent therapeutic effect and a low barrier to resistance. New nucleos(t)ide analogues (entecavir and tenofovir) eliminate virus more effectively with few adverse reactions, and may replace lamivudine or HBIG in future.CONCLUSIONS:Hepatitis B vaccine needs further largescale and rigorous randomized controlled trials to confirm its effective dose and injection frequency. Monoclonal antibody is still experimental, and the next step is to carry out the relevant animal and human studies. A consensus standard regimen for the treatment of hepatitis B should be developed.

    (Hepatobiliary Pancreat Dis Int 2010; 9: 15-21)

    hepatitis B vaccination;hepatitis B immunoglobulin; lamivudine; liver transplantation; adefovir; hepatitis B virus; genotype

    Introduction

    Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic diseases. About 2 billion people worldwide have been infected with the virus and about 350 million live with chronic infection. An estimated number of 600 000 persons die each year from the acute or chronic consequences of hepatitis B.

    Liver transplantation is a radical cure for posthepatitis B virus (HBV)-related cirrhosis and hepatocellular carcinoma. In Japan, the morbidity of post-HBV-related liver cirrhosis is about 13.9%.[1]In China, HBV related diseases is the most common primary reason for liver transplantation (78.6%).[2]Although liver transplantation can alleviate clinical symptoms such as ascites, hepatic encephalopathy, hypoalbuminemia, and infection, the adverse effects of immunosuppressive drugs raise the possibility of HBV recurrence or virus breakthrough.[3]Choosing the right prophylactic drug to control the HBV DNA load at an acceptable level is very important.

    Immunotherapy is a promising treatment that can enhance the body's ability to resist viruses. Traditional non-specific immune therapy is a passive one such as HBIG. Then studies have been concentrated onthe specific immune therapy for stimulating active immunity-vaccines. The development of new vaccines that stimulate an effective immune response when patients receive an organ transplant is a hot topic. Recently, Pan et al[4]synthesized engineered mAbs that showed inhibition of HBVin vitro.

    Various monotherapies and combinations have been developed for the treatment of hepatitis B.[5,6]These drugs have played important therapeutic roles, and they also have inherent disadvantages such as adverse reactions, hepatitis B recurrence, and long-term drugresistant strains. Viral resistance mechanisms and the pharmacoeconomics of combination therapy have been reported.[7]

    Immunotherapy

    Hepatitis B vaccination: dose and phase?

    Inducing an active immune response against the hepatitis B surface antigen (HBsAg) leads to continuous secretion of specific antibodies. The vaccine is given in either three or four separate doses as part of the existing routine immunization schedule. The safe anti-HBs titer for continuous prevention of HBV reinfection varies in some studies. Relatively low seroconversion rates and serum anti-HBs concentrations are reported among chronic HBV-infected liver transplantation recipients; only a minority of vaccines may have stable antibody levels >100 IU/L.[8]In the past, anti-HBs-positive individuals (seropositivity: anti-HBs titer of >10 IU/L) have always been considered safe to receive orthotopic liver transplantation for non-HBV-related diseases. Five of ninede novoHBV-infected patients were anti-HBs positive before orthotopic liver transplantation.[9]So, for prevention ofde novoHBV infection after transplantation, the protective anti-HBs titer should be >200 IU/L.[10]

    It has been reported that the response rate to HBV vaccine is significantly lower in patients with liver cirrhosis, immunocompromised patients, or organ transplant recipients.[8]When discussing immune status including T-cell and B-cell activity with response rate, Tahara et al[11]found that T-cell interactions which lead to an effective immune response to hepatitis B vaccination can cause activation of anti-HBsAg-specific T cells and suppression of anti-donor-specific T cells. Patients showing a donor-specific hyporesponse with a well-maintained response to a third-party (exogenous) stimulus always have a sustained immune response to the vaccine. Another study on T-cell immunity found that in 12 orthotopic liver transplantation recipients with HBV recurrence, the HBV-specific T-cell immunity was enhanced to a level comparable to that of patients with chronic hepatitis B, and the level was dependent on the serum viral load. Thus this raises an interesting question whether the higher response in theresearch of Tahara et al is really due to the donor-specific hyporesponse or just to the activity of anti-HBsAgspecific T cells or both. Schumann et al[12]demonstrated that HBV-specific humoral and cellular immunity can be transferred by liver transplantation after vaccination of the donor. The transfer of B-cell and T-cell immunity correlates with the magnitude of the immune responses in the donor.

    Table. Comparison of four studies of hepatitis B vaccination

    The response rate of liver transplantation candidates (with HBV-unrelated liver failure) to recombinant hepatitis B vaccination varies from 16% to 62%.[13]Many variables are associated with the response rate, the most important being the injection frequency and dose per injection. The Table shows four different studies of hepatitis B vaccination. Although these studies may be incompletely randomized or lack proper controls they show that 3-4 doses (40 μg), which can stimulate the necessarily response rate (30%-41%), are optimal for vaccination. But the HBsAb titer of responders varies a lot. Larger randomized controlled trials with good quality controls and design will provide more distinct answers about the dose, phase and response rate of hepatitis B vaccination.

    In special patients, the existing routine immunization schedules may not be equally effective as in normal people. Yamashiki et al[14]investigated 18 patients who underwent liver transplantation for chronic hepatitis B and 2 non-HBV-infected patients who received hepatitis B core antibody (HBcAb)-positive donor organs; doubledose double-phase use of second-generation recombinant vaccine was not effective in preventing hepatitis B recurrence in the study population. These populations should be targeted for a conventional vaccine regimen, and different approaches such as strong adjuvant or pre-S containing protein should be further tested.

    Vaccination also shows differences in sex, both in adult and pediatric liver transplantation groups. Girls respond with higher anti-HBs titres than boys, as do women.[18,19]It has become an interesting controversy whether the treatment is individualized to different ethnicities or groups of people. Ni et al[19]found that more than half of the children who were primarily vaccinated with HBV vaccines maintained adequate anti-HBs titers 1 year later after liver transplantation. All consecutive patients maintain a certain degree of cellular immune response irrespective of their anti-HBs status after liver transplantation. We expect that one or more doses of booster may help children who receive transplantation to develop protective response to anti-HBs.

    Human mAb: a novel approach?

    High specificity monoclonal antibodies to pathogens such as human papilloma virus have greatly expanded therapeutic methodology. Genetically engineered mAbs specific to the surface antigens of HBV would be a good alternative for the immunoprophylaxis of HBV infection.[20]Thus Pan et al[4]cloned the gene of a high Fab-affinity antibody from human peripheral blood and constructed Fab antibody rAAV-HB. After evaluating the activity of antibody hepatitis B in tree shrews treated with intramuscular injection of rAAV-HB andin vitroexperiments, they concluded that human antibody will be useful for the immunoprophylaxis of HBV infection, but this needs further study in human experiments. The safety and efficiency of transgenic drugs is controversial, which may restrict the use of engineered monoclonal antibodies.

    Drug regimens

    HBIG and lamivudine combination: low-dose intramuscular or high-dose intravenous HBIG?

    The HBIG (10 000 IU per month) and lamivudine regimen used to be the gold standard for prophylaxis against HBV recurrence after liver transplant. This therapy reduces the risk of recurrence to less than 5% at 5 years.[21]However, the cost of HBIG has driven people to investigate a lowdose of intramuscular HBIG (400-800 IU per month) and lamivudine in combination. This combination can achieve the same prophylaxis effect at a lower cost.[22]In Tashiro's research,[23]although two patients were preoperatively HBV DNA-positive shown by a transcription-mediated amplification assay method, all 14 patients receiving a high dose (10 000 IU/day) of HBIG and lamivudine in combination postoperatively became HBV-DNA-negative and HBsAg-negative.

    In Chinese liver transplant patients, the efficacy of HBIG was found to be associated with human leukocyte Fcγ receptor 3A gene polymorphisms (at nucleotide site 559). Among the 559G carrier group (n=42, 54.5%), the risk of HBV recurrence was 9.5%, and the 1- and 2-year recurrence-free survival rates were 95.2% and 88.7%, respectively. In the 559G noncarrier group (n=35, 45.5%), the risk of HBV recurrence was 28.6%, and the 1-and 2-year recurrence-free survival rates were 74.3% and 69.3%. Detecting FCGR3A genotypes can be a clinical reference for treatment before HBIG administration.[24]

    Hooman et al[25]pointed out that administration of intravenous HBIG (2000 IU per six weeks) and intramuscular administration of HBIG (2000 IU per six weeks) are equally effective with antibody against hepatitis B surface antigen (anti-HBs) in pharmacokinetics. Intramuscular HBIG may not be dose-saving; however, it may be cost-effective if the price per unit of intramuscular HBIG is lower. Individualized dosing intervals should be further evaluated as a cost-effective alternative to fixed dose schemes.

    Saab et al[26]compared prophylaxis with lamivudine and adefovir (strategy 1), with intramuscular HBIG and lamivudine (strategy 2) with the addition of adefovir in patients who subsequently developed hepatitis B recurrence. The medical costs for strategies 1 and 2 after 10 years of therapy were $151819 and $166246, respectively, and the cost saving was $14427. They developed a Markov model to provide pharmacoeconomic support for the use of strategy 1 as first-line therapy in hepatitis B prophylaxis in liver transplant recipients 1 year after transplantation. Strategy 1 not only decreased the total fee for preventing hepatitis B after liver transplantation, but also improved the quality of life. Administration of HBIG requires frequent blood tests to assess antibody titers. On the other hand, adefovir is an oral medication with rare adverse effects and less demand for frequent monitoring.

    High-dose HBIG during the ahepatic period and in the early stage of post transplantation can fulfill the treatment target as a long-term lamivudine therapy before liver transplantation. Long-term preoperative lamivudine treatment may result in an earlier HBV mutation in YMDD and increase the HBV recurrence rate and risk in the first year after transplantation.[27]Yilmaz et al[28]found that recurrence can be prevented in E-antigen-negative patients with HBIG alone or in E-antigen-positive patients with a combination of HBIG and an anti-viral agent. Eight out of fifteen E-antigen-positive patients who received HBIG alone developed recurrence after a mean of 17 months. As long as the anti-HBV surface remained detectable, no absolute minimum serum level appeared to lead to recurrent HBV. But the question is raised whether this combination or use of HBIG alone should be continued within 1 year after operation.

    Polyvalent immunoglobulin can cause nephrotoxicity. Pathologic examination of the kidneys generally reveals changes typical of osmotic nephrosis. The inappropriate use of HBIG can increase the risk of renal dysfunction, particularly in combination with nephrotoxic drugs.[29]

    Lamivudine and adefovir dipivoxil regimen: effective and easy to get

    Lamivudine and adefovir represent two different classes of anti-HBV agents (L-nucleoside and acyclic phosphonate) with different mechanisms of action, and there is no cross-resistance between them. Their combination greatly reduces the risk of subsequent adefovir resistance in nontransplantation patients.[30]Prophylaxis combined with adefovir/lamivudine therapy without the use of long-term HBIG is effective and well tolerated.[31]Meanwhile we cannot exclude the possibility that with a prolonged follow-up, some patients may experience viral breakthrough due to the appearance of lamivudine/adefovir resistance.[5]

    Before liver transplantation, lamivudine was proposed to be down-graded from the first to second-line therapy. In contrast, adefovir dipivoxil has been approved not only as the first-line therapy but also as rescue therapy for patients with lamivudine resistance.[32]A retrospective cohort study evaluated the safety and efficacy of adefovir in 68 elderly and cirrhotic patients with lamivudine-resistant chronic hepatitis B, among whom 75.4% received a combination treatment with lamivudine and adefovir for a median duration of 12.6 months; the remaining patients received adefovir overlapping with lamivudine treatment for a median duration of 7.9 months. At the end of the follow-up, 41.2% of the patients had undetectable HBV DNA (≤2000 copies/ml) with a median reduction of lg3.4 copies/ ml. No resistance mutations and no significant side effects were observed.[33]Even though no combination treatment can cover all the possible mutation strains, we focus on reducing the resistance as much as possible to get a good prognosis.

    A seven-year follow-up study of 24 patients showed that HBV recurrence developed in 7 patients with cumulative probabilities of 8%, 13%, 28%, 35%, 35%, and 49% in 1, 2, 3, 4, 5, and 6 years. Four patients had rtM204I mutation, and in 3 of them HBV DNA levels were too low for sequencing. After use of lamivudine followed by adefovir salvage for 150 weeks (91-193), 6 (86%) patients had normal ALT levels. HBV DNA was undetected in 2 (29%) patients, 100-1000 copies/ml in 2 (29%) and 10 000-100 000 copies/ml in 3 (43%) on the last visit. No genotypic resistance to adefovir was detected,[34]showing that lamivudine followed by adefovir salvage is effective for prophylaxis of recurrence of HBV for up to 7 years after liver transplantation.

    Management of YMDD mutant: lamivudine, adefovir and HBIG triple therapy

    YMDD mutation is common in the application of lamivudine in treating HBV. In 183 adult liver transplantation patients who lived more than 6 months and were followed up for 14.6 months, the rate of YMDD mutation in the lamivudine group was 8.49% (9/106), markedly higher than that in the lamivudine+HBIG group (1.30%, 1/77;P=0.035). The patients with YMDDmutation improved after treatment with adefovir.[35]

    4.烤箱預(yù)熱至160度,取烤盤、上置一烤架,雞置于烤架上(雞背向上),烤盤置于烤箱最下層,烘烤時(shí)間為每1000克雞烤35-40分鐘。每過(guò)45分鐘將烤盤中的湯汁和雞油,收集起來(lái)倒在另一盆內(nèi)。同時(shí)將雞翻一次身。

    In patients with YMDD mutation at the time of transplantation, combined use of HBIG and lamivudine is not consistently successful in preventing reinfection. In this situation, the addition of another antiviral agent combating the drug-resistant virus (i.e., adefovir, tenofovir, or entecavir) would be expected to further reduce the risk of prophylaxis failure.[36]

    As described in a ten-year study from Ikegami et al,[37]patients with YMDD mutation (9 of 29 patients), except an HBsAg-positive donor, were successfully protected by the triple therapy of lamivudine, adefovir, and HBIG. No graft loss was due to the recurrence of HBV. YMDD mutation should be closely monitored during lamivudine treatment.[38]

    Other oral nucleos(t)ide analogues: entecavir and tenofovir

    Entecavir is a guanosine nucleotide analogue. It is a new, highly potent antiviral agent; phase Ⅱ and Ⅲstudies have demonstrated this drug to be superior to placebo and lamivudine in patients with chronic HBV.[39]Because of the low resistance barrier, it used to be a substitute for lamivudine-resistant patients. Kurashige et al[40]recommended that lamivudine-to-entecavir switching treatment may be suitable in chronic hepatitis B patients without evidence of lamivudine resistance during the preceding lamivudine treatment with great attention to the emergence of entecavir-resistance.

    Kamar et al[41]reported that 10 male transplant patients with chronic HBV infection who were adefovir-(n=9) or lamivudine-resistant (n=1) were given entecavir at 0.5 to 1 mg/d. All patients were HBsAg-positive. After a median follow-up of 16.5 months, entecavir therapy reduced the HBV DNA viral load from lg3.86 (lg2.71-lg6.46) copies/ml at baseline to lg2.94 (lg2.15-lg4) copies/ml at the last follow-up (P=0.004). The host biological response was better in kidney transplant patients than in liver transplant patients because HBV has a liver tropism which may be more resistant and more aggressive in a transplanted liver than in a native one.[41]This study showed good results of entecavir in treating kidney or liver transplant patients, which may be used in treatment of liver-kidney transplantation patients.

    Tenofovir is an acyclic nucleotide analog, reverse transcriptase inhibitor.[42]Zhu et al[43]compared different regimens of tenofovir with lamivudine, entecavir, and adefovir. They found that of combinations lamivudine+tenofovir, entecavir+tenofovir, and adefovir+ tenofovir showed additive anti-HBV effectsin vitro. This supports the use of tenofovir as a component in combination regimens with currently available anti-HBV nucleoside analogues.

    Benefits and risks of combination therapy

    Many reports describe the benefits and risks of hepatitis B drug treatment. This section just mentions some special points of liver transplantation. Combination therapy for hepatitis B is recommended in specific patients: those who have undergone liver transplantation, those with decompensated cirrhosis, those coinfected with human immunodeficiency virus and HBV who are on antiretroviral therapy, and those with drug-resistant HBV infection.[44]In successful antiviral combination therapy, different drug regimens may cover major virus mutation pathways to minimize possible drug resistance. However, investigators still find many different mutations in response to the first line drugs such as lamivudine with rtM204V, rtL180M, and rtS202G mutations.[40]These mutations may cause virus recurrence and lead to transplant failure. Thus it is important to monitor the status of patients during therapy. Monitoring of treatment response includes tests for serum aminotransferase level, HBV DNA level, hepatitis B e antigen (HBeAg) and antibody (anti-HBe), hepatitis B surface antigen (HBsAg) or antibody (anti-HBs), and liver histology.[45]Early discovery of possible drug resistance may contribute to a good prognosis of liver transplantation.

    Genetic factors and drug therapy: individual treatment

    Eight distinct genotypes of HBV A to H have been identified, each having a characteristic geographic distribution.[46,47]Each genotype can be divided into many subtypes like B1-B4, and C1-C4. In China, B2 and C2 predominate.[48]Genotype can effect graft survival rate and the cumulative rate of viral breakthrough. Lo et al[49]found that genotype B patients have more pre-transplant acute flare, poorer liver functions, and higher end-stage liver disease scores. Fewer genotype B patients have HBeAg (13% vs. 32%;P=0.017). The 3-year graft survival rate is 83% for genotype B and 89% for genotype C (P=0.2). The graft survival due to lamivudine-resistant mutation at 3 years is 4% for genotype B and 21% for genotype C (P=0.017). Liver biopsy after viral breakthrough showed recurrent hepatitis B in 7 of 10 genotype C patients.

    Gene polymorphism also contributes to host immune behavior to HBV and drugs, such as mutations of the gene coding for the major hydrophilic region of HBsAg may be associated with anti-HBs immunoglobulins or vaccine escape.[50]In Chinese liver transplantation, the organ recipients with CTLA-4 +49 GG genotype have a reduced risk (6.67%,n=11) of HBV recurrence comparedwith non-CTLA-4 +49 GG-carrying individuals (20.7%) (relative risk 3.098;P=0.032).[51]

    After ending of the human genome project, the concept of molecular medicine has emerged. The evidence mentioned above can lead to early diagnosis and genetic prediction of HBV infection or recurrence. Before prescribing a drug in future we may review the genetic characteristics of a patient and decide the best choice of therapy.

    In conclusion, further research is needed to provide evidence-based recommendations about optimal antiviral therapy in adults with chronic hepatitis B infection. Monoclonal antibodies are still in the experimental stage, and the next step is taken to do relevant animal and human studies. A consensus on a standard regimen for the treatment of hepatitis B should be achieved.

    Funding:This study was supported by grants from the Key Program of National Natural Science Foundation of China (30730085) and the National High Technology Research and Development Program of China (863 Program; 2006AA 02A412).

    Ethical approval:Not needed.

    Contributors:ZJ wrote the main body of the article under the supervision of ZL and ZSS. ZL and ZSS provided advice on medical aspects. ZSS is the guarantor.

    Competing interest:No bene fits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

    1 Michitaka K, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y, Onji M, et al. Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol 2009.

    2 Zhao J, Yan L, Li B, Zeng Y, Wen T, Zhao J, et al. Diabetes mellitus after living donor liver transplantation: data from mainland China. Transplant Proc 2009;41:1756-1760.

    3 Lok AS. How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting. Liver Transpl 2008;14:S8-S14.

    4 Pan T, Cai M, Tang L, Zhou LQ, Li BJ, Zhu T, et al. A novel approach of prophylaxis to HBV recurrence after liver transplantation. Virology 2008;382:1-9.

    5 Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008;48:1460-1466.

    6 Zhang FK, Zhang Y, Zhang JY, Jia JD, Wang BE. Favorable outcome of de novo hepatitis B infection after liver transplantation with lamivudine and adefovir therapy. Transpl Infect Dis 2009;11:549-552.

    7 Avolio AW, Nure E, Pompili M, Barbarino R, Basso M, Caccamo L, et al. Liver transplantation for hepatitis B virus patients: long-term results of three therapeutic approaches. Transplant Proc 2008;40:1961-1964.

    8 Castells L, Esteban R. Hepatitis B vaccination in liver transplant candidates. Eur J Gastroenterol Hepatol 2001;13:359-361.

    9 Bárcena Marugán R, García-Hoz F, Vázquez Romero M, Nash R, Mateos M, González Alonso R, et al. Prevention of de novo hepatitis B infection in liver allograft recipients with previous hepatitis B infection or hepatitis B vaccination. Am J Gastroenterol 2002;97:2398-2401.

    10 Su WJ, Ho MC, Ni YH, Chen HL, Hu RH, Wu YM, et al. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr 2009;48:203-208.

    11 Tahara H, Tanaka Y, Ishiyama K, Ide K, Shishida M, Irei T, et al. Successful hepatitis B vaccination in liver transplant recipients with donor-specific hyporesponsiveness. Transpl Int 2009;22: 805-813.

    12 Schumann A, Lindemann M, Valentin-Gamazo C, Lu M, Elmaagacli A, Dahmen U, et al. Adoptive immune transfer of hepatitis B virus specific immunity from immunized living liver donors to liver recipients. Transplantation 2009;87:103-111.

    13 Takemura N, Sugawara Y, Tamura S, Makuuchi M. Liver transplantation using hepatitis B core antibody-positive grafts: review and university of Tokyo experience. Dig Dis Sci 2007; 52:2472-2477.

    14 Yamashiki N, Sugawara Y, Tamura S, Kaneko J, Matsui Y, Togashi J, et al. Double-dose double-phase use of second generation hepatitis B virus vaccine in patients after living donor liver transplantation: Not an effective measure in transplant recipients. Hepatol Res 2009;39:7-13.

    15 Pascasio JM, AoufiS, Gash A, Sousa JM, Perea R, Sayago M, et al. Response to a vaccination schedule with 4 doses of 40 microg against hepatitis B virus in cirrhotic patients evaluated for liver transplantation. Transplant Proc 2008;40:2943-2945.

    16 Bonazzi PR, Bacchella T, Freitas AC, Osaki KT, Lopes MH, Freire MP, et al. Double-dose hepatitis B vaccination in cirrhotic patients on a liver transplant waiting list. Braz J Infect Dis 2008;12:306-309.

    17 Jin SJ, Lu SC, Lai W, Dai J, Zhao J, Li YP, et al. Enhancing active immunity against hepatitis B virus by HBV vaccine immunization in patients with HBV-related end-stage liver diseases treated with liver transplantation. Zhonghua Gan Zang Bing Za Zhi 2008;16:261-264.

    18 Fang JW, Lai CL, Chung HT, Wu PC, Lau JY. Female children respond to recombinant hepatitis B vaccine with a higher titre than male. J Trop Pediatr 1994;40:104-107.

    19 Ni YH, Ho MC, Wu JF, Chen HL, Wu YM, Hu RH, et al. Response to booster hepatitis B vaccines in liver-transplanted children primarily vaccinated in infancy. Transplantation 2008;86:1531-1535.

    20 Hong HJ, Ryu CJ, Hur H, Kim S, Oh HK, Oh MS, et al. In vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees. Virology 2004;318:134-141.

    21 Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int 2009; 29:1294-1305.

    22 Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000;6:429-433.

    23 Tashiro H, Itamoto T, Fudaba Y, Ohdan H, Fukuda S, KohashiT, et al. Prophylaxis against recurrence of HBV hepatitis after living-donor liver transplantation. Hepatogastroenterology 2008;55:1746-1749.

    24 Wang WL, Zhang GL, Wu LH, Yao MY, Jin J, Jia CK, et al. Efficacy of hepatitis B immunoglobulin in relation to the gene polymorphisms of human leukocyte Fcgamma receptor III (CD16) in Chinese liver transplant patients. Chin Med J (Engl) 2007;120:1606-1610.

    25 Hooman N, Rifai K, Hadem J, Vaske B, Philipp G, Priess A, et al. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl 2008;14:435-442.

    26 Saab S, Ham MY, Stone MA, Holt C, Tong M. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. Liver Transpl 2009;15:413-420.

    27 Lu AW, Zheng SS, Wu MP, Shen Y, Yang RW. Reevaluation of the effect of lamivudine therapy preoperative to prevent HBV recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2008;7:357-361.

    28 Yilmaz N, Shiffman ML, Todd Stravitz R, Sterling RK, Luketic VA, Sanyal AJ, et al. Prophylaxsis against recurrance of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years. Liver Int 2008;28:72-78.

    29 Angeli P, Scaglione F. Nephrotoxicity of intravenous immunoglobulin in the setting of liver transplantation or HBV-related cirrhosis: an undervalued topic. Minerva Gastroenterol Dietol 2008;54:259-275.

    30 Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007;133:1445-1451.

    31 Patterson SJ, Angus PW. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues. Curr Opin Organ Transplant 2009;14:225-230.

    32 Jiang L, Jiang LS, Cheng NS, Yan LN. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2009;15:2489-2499.

    33 Zoulim F, Parvaz P, Marcellin P, Zarski JP, Beaugrand M, Benhamou Y, et al. Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. Liver Int 2009;29:420-426.

    34 Limquiaco JL, Wong J, Wong VW, Wong GL, Tse CH, Chan HY, et al. Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study. J Med Virol 2009;81:224-229.

    35 Zhang XL, Zhu XF, Shi HJ, Cui SZ, Tang YQ, Ba MC, et al. Prevention and treatment of hepatitis B recurrence after liver transplantation. Zhonghua Yi Xue Za Zhi 2008;88:606-609.

    36 Samuel D. The option of liver transplantation for hepatitis B: where are we? Dig Liver Dis 2009;41:S185-189.

    37 Ikegami T, Soejima Y, Ohta R, Taketomi A, Yoshizumi T, Harada N, et al. Living donor liver transplantation for hepatitis B associated liver diseases: a 10-year experience in a single center. Hepatogastroenterology 2008;55:1445-1449.

    38 Gwak GY, Huh W, Lee DH, Choi MS, Lee JH, Koh KC, et al. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy. Transplant Proc 2007;39: 3121-3126.

    39 Calleja JL, Penas B. Enferm Infecc Microbiol Clin 2008;26:S39-48.

    40 Kurashige N, Ohkawa K, Hiramatsu N, Yakushijin T, Mochizuki K, Oze T, et al. Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance. J Gastroenterol 2009;44:864-870.

    41 Kamar N, Milioto O, Alric L, El Kahwaji L, Cointault O, Lavayssière L, et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008;86:611-614.

    42 Reynaud L, Carleo MA, Talamo M, Borgia G. Tenofovir and its potential in the treatment of hepatitis B virus. Ther Clin Risk Manag 2009;5:177-185.

    43 Zhu Y, Curtis M, Qi X, Miller MD, Borroto-Esoda K. Antihepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues. Antivir Chem Chemother 2009;19:165-176.

    44 Terrault NA. Benefits and risks of combination therapy for hepatitis B. Hepatology 2009;49:S122-128.

    45 Andersson KL, Chung RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatology 2009;49:S166-173.

    46 Fung SK, Lok AS. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 2004;40: 790-792.

    47 Echevarría JM, Avellón A. Hepatitis B virus genetic diversity. J Med Virol 2006;78:S36-42.

    48 Norder H, Couroucé AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004;47:289-309.

    49 Lo CM, Cheung CK, Lau GK, Yuen MF, Liu CL, Chan SC, et al. Significance of hepatitis B virus genotype in liver transplantation for chronic hepatitis B. Am J Transplant 2005; 5:1893-1900.

    50 Roque-Afonso AM, Ferey MP, Belkhiri D, Dussaix E. HBs antigen mutants: prevalence, clinical and diagnostic implications. Pathol Biol (Paris) 2005;53:563-568.

    51 Jiang Z, Feng X, Zhang W, Gao F, Ling Q, Zhou L, et al. Recipient cytotoxic T lymphocyte antigen-4 +49 G/G genotype is associated with reduced incidence of hepatitis B virus recurrence after liver transplantation among Chinese patients. Liver Int 2007;27:1202-1208.

    October 22, 2009

    Accepted after revision December 23, 2009

    Author Affiliations: Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health; Key Laboratory of Organ Transplantation, Zhejiang Province; First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China (Zhang J, Zhouland Zheng SS)

    Shu-Sen Zheng, MD, PhD, FACS, Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China (Tel: 86-571-87236601; Email: shusenzheng@zju.edu.cn)

    ? 2010, Hepatobiliary Pancreat Dis Int. All rights reserved.

    直男gayav资源| 亚洲欧美清纯卡通| 日本wwww免费看| 肉色欧美久久久久久久蜜桃| av在线app专区| 成人国产麻豆网| 身体一侧抽搐| 永久免费av网站大全| 纵有疾风起免费观看全集完整版| 亚洲熟女精品中文字幕| 菩萨蛮人人尽说江南好唐韦庄| 久久久久久久久大av| 精品少妇黑人巨大在线播放| 最近手机中文字幕大全| 精品国产乱码久久久久久小说| 夜夜看夜夜爽夜夜摸| 性色av一级| 一本色道久久久久久精品综合| av福利片在线观看| kizo精华| 天天躁日日操中文字幕| av国产免费在线观看| 国产永久视频网站| 国产成人精品福利久久| 国产精品国产av在线观看| 在线亚洲精品国产二区图片欧美 | 新久久久久国产一级毛片| 王馨瑶露胸无遮挡在线观看| 18禁裸乳无遮挡动漫免费视频| av播播在线观看一区| 少妇人妻 视频| 精品亚洲成国产av| 天美传媒精品一区二区| 一区在线观看完整版| 精品少妇黑人巨大在线播放| 99久久精品一区二区三区| 亚洲精品国产av蜜桃| 欧美丝袜亚洲另类| 亚洲av免费高清在线观看| 好男人视频免费观看在线| 免费观看无遮挡的男女| 各种免费的搞黄视频| 欧美bdsm另类| 蜜臀久久99精品久久宅男| 免费观看在线日韩| 99国产精品免费福利视频| 99久久精品一区二区三区| 亚洲人成网站高清观看| 欧美 日韩 精品 国产| 少妇熟女欧美另类| 久久精品国产亚洲网站| 亚洲av不卡在线观看| 免费黄频网站在线观看国产| 美女脱内裤让男人舔精品视频| 亚洲熟女精品中文字幕| 久久 成人 亚洲| 18禁在线无遮挡免费观看视频| 少妇人妻精品综合一区二区| 熟女av电影| 91午夜精品亚洲一区二区三区| xxx大片免费视频| 能在线免费看毛片的网站| 成人二区视频| 国产精品.久久久| 婷婷色综合大香蕉| 欧美xxxx黑人xx丫x性爽| 精品99又大又爽又粗少妇毛片| 99国产精品免费福利视频| 亚洲真实伦在线观看| 97在线视频观看| av女优亚洲男人天堂| 国产成人精品一,二区| 熟女电影av网| 一级片'在线观看视频| 国产精品熟女久久久久浪| 在线观看人妻少妇| 日本黄大片高清| 免费不卡的大黄色大毛片视频在线观看| 好男人视频免费观看在线| 亚洲精品乱码久久久v下载方式| 国产欧美亚洲国产| 亚洲伊人久久精品综合| 国产视频首页在线观看| 一区二区三区精品91| 亚洲国产色片| 日韩中字成人| 久久久午夜欧美精品| 亚洲精品亚洲一区二区| freevideosex欧美| 婷婷色麻豆天堂久久| 街头女战士在线观看网站| 国产91av在线免费观看| 91精品伊人久久大香线蕉| 在现免费观看毛片| 久久国内精品自在自线图片| 中文字幕久久专区| 国产极品天堂在线| av国产精品久久久久影院| 久久久久性生活片| 日韩国内少妇激情av| 亚洲熟女精品中文字幕| 国精品久久久久久国模美| 欧美 日韩 精品 国产| 久久久久国产网址| 亚洲欧洲国产日韩| 久久国内精品自在自线图片| 国产又色又爽无遮挡免| 这个男人来自地球电影免费观看 | 免费看光身美女| 全区人妻精品视频| 又粗又硬又长又爽又黄的视频| 在现免费观看毛片| 国产欧美日韩精品一区二区| 欧美 日韩 精品 国产| 18禁在线播放成人免费| 内射极品少妇av片p| 精品酒店卫生间| 91久久精品电影网| 久久久久国产网址| 亚洲欧美一区二区三区黑人 | 欧美精品一区二区大全| 免费观看在线日韩| 欧美xxⅹ黑人| 1000部很黄的大片| 你懂的网址亚洲精品在线观看| 精品国产一区二区三区久久久樱花 | 日本爱情动作片www.在线观看| 夫妻午夜视频| 一区二区三区免费毛片| 亚洲精品国产av蜜桃| 熟女av电影| 久久ye,这里只有精品| a级毛片免费高清观看在线播放| 成人特级av手机在线观看| 亚洲自偷自拍三级| 自拍偷自拍亚洲精品老妇| 久久久成人免费电影| 日韩强制内射视频| 亚洲精品国产成人久久av| 国产成人免费无遮挡视频| 噜噜噜噜噜久久久久久91| 日本猛色少妇xxxxx猛交久久| 视频中文字幕在线观看| 久久国产亚洲av麻豆专区| 国产综合精华液| 天美传媒精品一区二区| 国产亚洲最大av| 国产精品女同一区二区软件| 青春草亚洲视频在线观看| 综合色丁香网| 18禁在线无遮挡免费观看视频| 99久久综合免费| 18禁裸乳无遮挡免费网站照片| 国产成人aa在线观看| 中文字幕免费在线视频6| 国产伦精品一区二区三区四那| 大话2 男鬼变身卡| 欧美日韩视频高清一区二区三区二| 欧美成人精品欧美一级黄| 老司机影院毛片| 丰满人妻一区二区三区视频av| 成人影院久久| 国产精品久久久久久久电影| 久久久色成人| 一边亲一边摸免费视频| 久久99热这里只有精品18| 国产男人的电影天堂91| 少妇的逼好多水| 91久久精品国产一区二区三区| 欧美日韩视频高清一区二区三区二| 18禁裸乳无遮挡免费网站照片| 热99国产精品久久久久久7| 51国产日韩欧美| 亚洲美女搞黄在线观看| 亚洲av成人精品一区久久| 美女中出高潮动态图| 国产欧美亚洲国产| 午夜福利在线在线| 欧美成人一区二区免费高清观看| 中文字幕人妻熟人妻熟丝袜美| 夜夜看夜夜爽夜夜摸| 亚洲国产欧美人成| 久久久久久久大尺度免费视频| 久久女婷五月综合色啪小说| 国产精品爽爽va在线观看网站| 国产精品久久久久久精品古装| 网址你懂的国产日韩在线| 亚洲一级一片aⅴ在线观看| 国产精品嫩草影院av在线观看| 另类亚洲欧美激情| 精品久久久久久电影网| 久久久久网色| 国产精品.久久久| 日韩三级伦理在线观看| 国产中年淑女户外野战色| 插逼视频在线观看| 自拍欧美九色日韩亚洲蝌蚪91 | 在现免费观看毛片| 国产欧美日韩精品一区二区| 18+在线观看网站| 黄色日韩在线| 一本色道久久久久久精品综合| 六月丁香七月| 日本黄色片子视频| 少妇精品久久久久久久| 国产高清不卡午夜福利| 26uuu在线亚洲综合色| 国产精品免费大片| 欧美性感艳星| 日日摸夜夜添夜夜爱| 亚洲欧美中文字幕日韩二区| a级毛色黄片| 老师上课跳d突然被开到最大视频| 赤兔流量卡办理| 成人亚洲精品一区在线观看 | 国产午夜精品久久久久久一区二区三区| 成人国产麻豆网| 男女国产视频网站| 免费观看的影片在线观看| 啦啦啦啦在线视频资源| 乱码一卡2卡4卡精品| 亚洲经典国产精华液单| 精品国产乱码久久久久久小说| 久久午夜福利片| 日韩欧美一区视频在线观看 | 欧美日韩视频高清一区二区三区二| 久久精品国产鲁丝片午夜精品| av网站免费在线观看视频| 亚洲色图综合在线观看| 亚洲人成网站在线观看播放| 丰满人妻一区二区三区视频av| 国产精品国产三级国产专区5o| 黄色日韩在线| 校园人妻丝袜中文字幕| 80岁老熟妇乱子伦牲交| 日韩精品有码人妻一区| 三级国产精品片| 大陆偷拍与自拍| av一本久久久久| 亚洲图色成人| 黄片无遮挡物在线观看| 亚洲综合精品二区| 国产在线男女| 十八禁网站网址无遮挡 | 两个人的视频大全免费| 久久热精品热| 26uuu在线亚洲综合色| 成人18禁高潮啪啪吃奶动态图 | 观看免费一级毛片| 黄色一级大片看看| 亚洲美女视频黄频| 欧美性感艳星| 一级黄片播放器| 秋霞伦理黄片| 在线天堂最新版资源| 视频区图区小说| 综合色丁香网| 人妻系列 视频| 成人午夜精彩视频在线观看| 边亲边吃奶的免费视频| 丰满人妻一区二区三区视频av| 毛片女人毛片| 国产日韩欧美亚洲二区| 最近中文字幕2019免费版| 亚洲伊人久久精品综合| 久久 成人 亚洲| 国产爽快片一区二区三区| h日本视频在线播放| 中国国产av一级| 欧美成人精品欧美一级黄| 精品久久久噜噜| 国产精品一区二区在线观看99| 国产爱豆传媒在线观看| 少妇丰满av| 伦理电影免费视频| 国产片特级美女逼逼视频| 精品人妻一区二区三区麻豆| 熟女电影av网| 亚洲欧美成人综合另类久久久| 国产精品一区二区性色av| 蜜桃在线观看..| 亚洲精品乱码久久久久久按摩| 最近中文字幕高清免费大全6| 秋霞在线观看毛片| 欧美一级a爱片免费观看看| 国产成人午夜福利电影在线观看| 久久人妻熟女aⅴ| 五月玫瑰六月丁香| 老司机影院成人| 欧美97在线视频| 天堂中文最新版在线下载| 精品久久国产蜜桃| 国产高清三级在线| 亚洲av男天堂| 国产久久久一区二区三区| 国产极品天堂在线| 亚洲欧美一区二区三区国产| 1000部很黄的大片| av不卡在线播放| videos熟女内射| 97超碰精品成人国产| 国产久久久一区二区三区| 国产伦精品一区二区三区四那| av网站免费在线观看视频| 高清av免费在线| 免费在线观看成人毛片| 伊人久久精品亚洲午夜| 哪个播放器可以免费观看大片| 99九九线精品视频在线观看视频| 久久久久久久国产电影| 亚洲国产高清在线一区二区三| av播播在线观看一区| 狂野欧美白嫩少妇大欣赏| 国产久久久一区二区三区| 男人狂女人下面高潮的视频| 香蕉精品网在线| 在线精品无人区一区二区三 | 午夜福利高清视频| 国产精品欧美亚洲77777| 建设人人有责人人尽责人人享有的 | 我要看黄色一级片免费的| 亚洲第一av免费看| 欧美三级亚洲精品| 久久久久视频综合| 久久精品夜色国产| 99re6热这里在线精品视频| 中文欧美无线码| 久久 成人 亚洲| 精品亚洲乱码少妇综合久久| 一级毛片黄色毛片免费观看视频| 亚洲国产欧美在线一区| 在线免费观看不下载黄p国产| 国产av一区二区精品久久 | 免费久久久久久久精品成人欧美视频 | 国产乱人视频| 亚洲av电影在线观看一区二区三区| 国产精品久久久久久久久免| 夫妻性生交免费视频一级片| 91aial.com中文字幕在线观看| 在线观看美女被高潮喷水网站| 国产91av在线免费观看| 两个人的视频大全免费| 国产男女内射视频| 国语对白做爰xxxⅹ性视频网站| 国产大屁股一区二区在线视频| 国产爱豆传媒在线观看| 国产综合精华液| 国产日韩欧美亚洲二区| 三级国产精品欧美在线观看| 亚洲内射少妇av| 亚洲精品日本国产第一区| 欧美+日韩+精品| 国产精品成人在线| av国产久精品久网站免费入址| 亚洲丝袜综合中文字幕| 深夜a级毛片| 国模一区二区三区四区视频| 久久国产精品男人的天堂亚洲 | 精品久久久久久电影网| 国产黄色视频一区二区在线观看| 伦精品一区二区三区| 国产成人91sexporn| 亚洲精品成人av观看孕妇| 三级经典国产精品| 高清av免费在线| 国产欧美日韩一区二区三区在线 | 国产伦理片在线播放av一区| 成人毛片60女人毛片免费| xxx大片免费视频| 国内精品宾馆在线| 国产欧美日韩精品一区二区| 精品久久久久久久久亚洲| 欧美日韩综合久久久久久| 免费播放大片免费观看视频在线观看| 日本欧美国产在线视频| 麻豆成人av视频| 国产一区二区在线观看日韩| 国语对白做爰xxxⅹ性视频网站| 久久久欧美国产精品| 99久久中文字幕三级久久日本| 欧美 日韩 精品 国产| 亚洲国产高清在线一区二区三| 国产亚洲最大av| av线在线观看网站| 亚洲精品亚洲一区二区| 好男人视频免费观看在线| 亚洲人成网站在线观看播放| 国产精品秋霞免费鲁丝片| 老司机影院成人| 久久久久久久久久成人| 久久久久久久久大av| 久久精品夜色国产| 性高湖久久久久久久久免费观看| 国产男人的电影天堂91| 国产精品久久久久久久久免| 国产免费福利视频在线观看| 偷拍熟女少妇极品色| 久久久久久久久久久丰满| 91久久精品电影网| 国产高清有码在线观看视频| 国产成人a区在线观看| 91aial.com中文字幕在线观看| 中文字幕精品免费在线观看视频 | 欧美成人精品欧美一级黄| 永久免费av网站大全| 免费观看性生交大片5| 在线观看一区二区三区激情| 亚洲av欧美aⅴ国产| 国精品久久久久久国模美| 少妇精品久久久久久久| 亚洲av中文av极速乱| 久久韩国三级中文字幕| 亚洲人成网站高清观看| 中文欧美无线码| 日韩亚洲欧美综合| 亚洲欧美日韩东京热| 2018国产大陆天天弄谢| 蜜桃久久精品国产亚洲av| 日本黄大片高清| 色视频在线一区二区三区| 精品亚洲成国产av| 亚洲精品久久久久久婷婷小说| 一二三四中文在线观看免费高清| 又黄又爽又刺激的免费视频.| 这个男人来自地球电影免费观看 | 精品久久久久久久久av| 亚洲av综合色区一区| av在线蜜桃| 啦啦啦中文免费视频观看日本| 成人综合一区亚洲| 国产一区二区在线观看日韩| 久久久久国产精品人妻一区二区| 国产精品久久久久久久电影| 久久99热这里只频精品6学生| 免费少妇av软件| 久久精品久久久久久久性| 九草在线视频观看| 成人特级av手机在线观看| 美女视频免费永久观看网站| 男女免费视频国产| 亚洲aⅴ乱码一区二区在线播放| kizo精华| 国产成人精品婷婷| av在线app专区| 观看av在线不卡| 麻豆精品久久久久久蜜桃| 边亲边吃奶的免费视频| 性色avwww在线观看| 精品酒店卫生间| 丰满迷人的少妇在线观看| av在线老鸭窝| 精品久久久久久久久亚洲| 精品人妻熟女av久视频| 色网站视频免费| 色视频在线一区二区三区| 成人一区二区视频在线观看| 国产成人91sexporn| 久久久久久久大尺度免费视频| 亚洲精品久久久久久婷婷小说| 男人爽女人下面视频在线观看| 夫妻性生交免费视频一级片| 久久青草综合色| kizo精华| 大片电影免费在线观看免费| 亚洲丝袜综合中文字幕| 九九在线视频观看精品| 少妇猛男粗大的猛烈进出视频| 人妻一区二区av| 欧美另类一区| 久久精品熟女亚洲av麻豆精品| 国产精品一及| 内地一区二区视频在线| 亚洲成人中文字幕在线播放| 人妻系列 视频| 久久久亚洲精品成人影院| 国产精品熟女久久久久浪| 大陆偷拍与自拍| 天天躁日日操中文字幕| 欧美激情极品国产一区二区三区 | 国产精品99久久99久久久不卡 | 久久99热这里只频精品6学生| 国产精品不卡视频一区二区| 高清av免费在线| 国产成人a区在线观看| 七月丁香在线播放| 高清毛片免费看| 精品国产乱码久久久久久小说| 欧美丝袜亚洲另类| 亚洲电影在线观看av| 能在线免费看毛片的网站| 人人妻人人澡人人爽人人夜夜| 免费观看性生交大片5| 麻豆成人av视频| 美女xxoo啪啪120秒动态图| 日韩在线高清观看一区二区三区| 国产精品欧美亚洲77777| 免费人成在线观看视频色| 国产成人精品婷婷| 99热这里只有是精品50| 高清日韩中文字幕在线| 蜜桃久久精品国产亚洲av| 3wmmmm亚洲av在线观看| 亚洲精品456在线播放app| 国产精品福利在线免费观看| 三级国产精品片| 国产亚洲5aaaaa淫片| 久久人人爽人人片av| 久久久午夜欧美精品| 午夜激情福利司机影院| 成人毛片a级毛片在线播放| 亚洲四区av| 身体一侧抽搐| 成年人午夜在线观看视频| 欧美区成人在线视频| 能在线免费看毛片的网站| 欧美区成人在线视频| 亚洲va在线va天堂va国产| 九九在线视频观看精品| 国语对白做爰xxxⅹ性视频网站| 久久久久久久久久人人人人人人| 午夜福利视频精品| 亚洲经典国产精华液单| 精品久久久久久久末码| 欧美最新免费一区二区三区| 91精品伊人久久大香线蕉| h日本视频在线播放| 91精品伊人久久大香线蕉| h日本视频在线播放| 欧美xxxx黑人xx丫x性爽| 国产高清不卡午夜福利| 王馨瑶露胸无遮挡在线观看| 欧美日韩综合久久久久久| 国产在视频线精品| 免费观看在线日韩| 国产精品熟女久久久久浪| 日韩欧美 国产精品| 精品一区二区三区视频在线| 欧美精品人与动牲交sv欧美| 乱系列少妇在线播放| 日韩av在线免费看完整版不卡| 少妇 在线观看| 免费人妻精品一区二区三区视频| 国产69精品久久久久777片| 久久国产乱子免费精品| 18禁动态无遮挡网站| 最新中文字幕久久久久| 亚洲不卡免费看| 亚洲国产精品专区欧美| 少妇精品久久久久久久| 午夜激情久久久久久久| 日韩一区二区视频免费看| 国国产精品蜜臀av免费| 18+在线观看网站| 少妇裸体淫交视频免费看高清| 免费看光身美女| 91精品国产国语对白视频| 精品酒店卫生间| 日日摸夜夜添夜夜爱| 色综合色国产| 精品久久久久久久末码| 亚洲电影在线观看av| 简卡轻食公司| 国产黄色免费在线视频| 免费看av在线观看网站| 久久久久精品久久久久真实原创| 亚洲av在线观看美女高潮| 一本色道久久久久久精品综合| 男人添女人高潮全过程视频| 一级毛片电影观看| 亚洲,欧美,日韩| 国产高清有码在线观看视频| 夫妻性生交免费视频一级片| 免费观看的影片在线观看| av网站免费在线观看视频| 三级国产精品片| 婷婷色综合大香蕉| 内地一区二区视频在线| 我的女老师完整版在线观看| 国产免费又黄又爽又色| 精品亚洲成国产av| 最近最新中文字幕免费大全7| 国产日韩欧美在线精品| 日本猛色少妇xxxxx猛交久久| 日韩一区二区视频免费看| 亚洲欧美精品专区久久| 不卡视频在线观看欧美| 久久97久久精品| 国产精品不卡视频一区二区| 国产免费福利视频在线观看| 一本一本综合久久| 中文天堂在线官网| 日韩一区二区三区影片| 精品人妻视频免费看| 内地一区二区视频在线| 最近最新中文字幕免费大全7| 亚洲精品中文字幕在线视频 | 极品教师在线视频| 亚洲伊人久久精品综合| 精品久久久噜噜| 国产成人免费观看mmmm| 国产91av在线免费观看| 日本vs欧美在线观看视频 | 欧美xxxx性猛交bbbb| 日本与韩国留学比较| 亚洲人成网站在线播| 爱豆传媒免费全集在线观看| 成人午夜精彩视频在线观看| 天堂8中文在线网| 人人妻人人澡人人爽人人夜夜| 国产精品熟女久久久久浪| 国产极品天堂在线| 久久久久久久国产电影| 亚州av有码| 欧美老熟妇乱子伦牲交| 在线观看免费高清a一片|